louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00957983: EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model
Official title: EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Headache, Migraine
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2009-08-13
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether EP-4 receptor antagonist can prevent the headache expected during a Prostaglandin E2 infusion.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers

Exclusion Criteria:

* Tension headache
* All other primary forms of headache
* Cardiovascular, Central Nervous system (CNS) and autoimmune diseases
* Gastrointestinal disease
* Previous or clinical signs of mental illness or substance abuse.
* Participation in a clinical study of a medicinal product without regulatory approval or marketing authorisation within 1 month prior to this trial
* Pregnancy/nursing
* Daily intake of medication (except oral contraceptives)

Primary outcomes:
measure: Headache
timeFrame: 24 hours
Secondary outcomes:
measure: rCBF, blood flow, diameter of STA/RA, HR, BP
timeFrame: in-hospital
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
Study officials:
affiliation: Danish Headache Center
name: Messoud Ashina, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02783183: A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin
Official title: A Open-label, Radomized, Crossover Clinical Trial to Assess the Pharmacokinetics of Pregabalin CR After Multiple Dosing as Compared to Pregabalin IR in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Peripheral Nueropathy Pain
Lead sponsor: Yuhan Corporation
Sponsor class: INDUSTRY
First posted: 2016-05-26
Enrollment: 32
Sex: MALE
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this trial to compare the pharmacokinetic characteristics of YHD1119(Pregabalin 300mg) and Lyrica capsule(Pregabalin 150mg). YHD1119 is controlled release formulation which is made by Yuhan Corporation. Primary endpoints are Cmax,ss and AUCtau and secondary endpoints are AUClast,ss, AUCinf,ss, Tmax,ss and t1/2.


Eligibility criteria: Inclusion Criteria:

* 19\~50 years old, healthy male volunteers
* \>55Kg(Body weight) and 18.5\<BMI\<28

Exclusion Criteria:

* AST or ALT \> 3 \* Upper normal range (Lab)
* Total bilirubin \> 2.0 mg/dl
* Systolic BP \>140 OR \<90, Diastolic BP \>100 OR \<60

Primary outcomes:
measure: Cmax,ss
timeFrame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
measure: AUCtau
timeFrame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
Secondary outcomes:
measure: AUClast,ss
timeFrame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
measure: AUCinf,ss
timeFrame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
measure: Tmax,ss
timeFrame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
Other outcomes:
Locations:
Study officials:
References:
citation: Moon SJ, Jeon JY, Lim Y, An T, Jang SB, Kim S, Na WS, Lee SY, Kim MG. Pharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers. Clin Ther. 2021 Aug;43(8):1381-1391.e1. doi: 10.1016/j.clinthera.2021.06.010. Epub 2021 Jul 11.
Clinical trial NCT00896883: Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum
Official title: A Prospective, Non-Randomized, Limited-Use Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sinusitis
Keywords: turbinate
implant
sinus surgery
Turbinates
Lead sponsor: ENTrigue Surgical, Inc.
Sponsor class: INDUSTRY
First posted: 2009-05-12
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the functional performance of the Middle Turbinate Implant (MTI). The MTI will be used in all patients requiring endoscopic sinus surgery in which the Principal Investigator determines clinical relevance.


Eligibility criteria: Inclusion Criteria:

* Subject is between the ages of 18 and 65 years and will be receiving endoscopic sinus surgery.
* Subject is able to provide a signed informed consent form.
* Subject will agree to comply with all study-related procedures.
* Subject is not pregnant at this time by confirmation of one of the following:

  * Subject is male
  * Subject not of child bearing age
  * Subject is surgically sterile
  * Subject is not pregnant per negative hCG test
  * Subject does not plan on becoming pregnant and is not breast feeding during the course of the study.

Exclusion Criteria:

* Subject does not meet inclusion criteria.
* Presence of non-viable tissue at the implantation site.
* History of septal perforation.
* History of polyps.
* Presence of concha bullosa.
* Subject is currently using CPAP (Continuous Positive Airway Pressure) for sleep apnea.
* Subject is participating in a clinical trial which could affect the healing of the middle turbinate.
* Subject has uncontrolled diabetes.
* Subject is a:

  * smoker
  * severe drug abuser
  * severe alcohol abuser
* Subject has an autoimmune disease deemed clinically significant by the Principal Investigator.

Primary outcomes:
measure: Functional performance of the MTI
timeFrame: 1 month
Secondary outcomes:
measure: Visual tissue reaction to the Middle Turbinate Implant
timeFrame: 1 month
Other outcomes:
Locations:
city: Sewell
country: United States
facility: Becker Nose and Sinus Center
state: New Jersey
city: Boerne
country: United States
facility: Texas Sinus Center
state: Texas
city: College Station
country: United States
facility: Texas ENT and Allergy
state: Texas
city: San Antonio
country: United States
facility: San Antonio Ear, Nose and Throat Research
state: Texas
Study officials:
affiliation: Texas ENT and Allergy
name: Ronald B Kuppersmith, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03174483: Radiologic Scoring of Patients With Chronic Sinusitis and Nasal Polyps
Official title: Effects of Hypertonic Saline and Fluticasone Nasal Sprays on Radiologic Scoring of Patients With Chronic Sinusitis and Nasal Polyps
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Sinusitis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-06-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To detect the effect of hypertonic saline and fluticasone sprays on computed tomography scan of paranasal sinuses of patients having chronic sinusitis and/or nasal polyps.


Eligibility criteria: Inclusion Criteria:

* Adult patients with chronic sinusitis and/or nasal polyps.

Exclusion Criteria:

* Patients with previous nasal or sinus surgery.
* Patients with sinonasal Malignancy.
* Immunocompromised patients.
* Patients with ciliary motility disorders.
* Pregnant women

Primary outcomes:
measure: The percentage of patient with normal radiological scoring
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References:
Clinical trial NCT00141583: The Renin-Angiotensin System in Essential Hypertension
Official title: The Renin-Angiotensin System in Essential Hypertension
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hypertension
Keywords: Renin-angiotensin system
ACE Inhibitor
Angiotensin Receptor Blocker
Lead sponsor: St George's, University of London
Sponsor class: OTHER
First posted: 2005-09-01
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.


Eligibility criteria: Inclusion Criteria:

* Essential Hypertension
* SBP 140-159 mmHg
* DBP 90-99 mmHg

Exclusion Criteria:

* Intolerance of or allergy to ACE Inhibitors or ARBS
* Pregnant or Breastfeeding
* Pre-menopausal women
* Uncontrolled cardiac or renal failure
* Diabetes mellitus

Primary outcomes:
measure: Change in BP
measure: Change in PRA and aldosterone
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL
Study officials:
affiliation: SGUL
name: Timothy WR Doulton, BSc MRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06398483: Comparative Study Between Micro Plate Fixation and Blocking k.Wire in Management of Acute Bony Mallet Finger : Randomized Controlled Clinical Trial Study
Official title: Comparative Study Between Micro Plate Fixation and Blocking k.Wire in Management of Acute Bony Mallet Finger : Randomized Controlled Clinical Trial Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acute Bony Mallet Finger
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-05-03
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mallet finger is an avulsion fracture of the distal phalanx or rupture of the extensor terminal band caused by distal interphalangeal (DIP) joint hyperflexion or axial loading. In the treatment of mallet finger fractures, surgical repair is recommended in cases where the fracture involves more than one-third of the distal phalanx joint surface or the distal phalanx becomes volar subluxated

The blocking k.wire and micro plate technique are some of the methods used in the treatment of mallet finger fractures In recent years, the blocking k.wire technique has gained popularity owing to its minimally invasive nature and its ability to achieve satisfactory postoperative results

The main advantages of Micro Plate technique include provision of anatomical reduction and stable fixation, avoiding the risk of fragmentation of the small dorsal fragment, allowing early movement and increasing patient comfort and compliance


Eligibility criteria: Inclusion Criteria:

- Acute bony mallet finger involves more than one third of the distal phalanx joint surface or the distal phalanx becomes volar sublaxed

Exclusion Criteria:

1- . crushed distal phalanx 2. soft tissue mallet 3. multiple phalangeal fractures 4. old neglected cases

Primary outcomes:
measure: post operative evalution of management of acute bony mallet finger
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
Clinical trial NCT04409483: Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
Official title: Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Covid-19
Lead sponsor: Epicentre
Sponsor class: OTHER
Collaborators: name: Université Abdou Moumouni
name: Centre de Recherche Médicale et Sanitaire
name: Ministry of Public Health, Republic of Niger
First posted: 2020-06-01
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed COVID-19 cases treated as outpatients.

Detailed description: After being informed about the study and potential risks, all patients who meet all eligibility criteria and who give written informed consent will be randomized to receive standard care or standard care plus lopinavir/ritonavir (400mg/100mg twice daily for 14 days). Participants will receive daily visits from study staff for 15 days and be followed for a total of 28 days.

Eligibility criteria: Inclusion Criteria:

* Suspect, probable or confirmed case of COVID-19
* Men and women aged ≥12 years, including pregnant and breastfeeding women
* SpO2 ≥93% on room air
* Signature of informed consent form

Exclusion Criteria:

* Medical indication for hospitalization at the time of enrolment
* Severe chronic liver disease
* Known infection with HIV
* Known allergy or severe intolerance to lopinavir/ritonavir
* Absolute contra-indication to lopinavir/ritonavir, including concomitant therapy with a medication whose metabolism is dependent on isoform CPY3A with a narrow therapeutic window (e.g., amiodarone, colchicine, simvastatin, lovastatin, etc.)
* Treatment with an antiviral medication in the 28 days prior to enrolment
* Dementia or other condition that interferes with active participation in data collection and obtaining informed consent

Primary outcomes:
measure: Hospitalization or death
timeFrame: 15 days following randomization
Secondary outcomes:
measure: All-cause mortality
timeFrame: 15 days following randomization
measure: All-cause mortality
timeFrame: 28 days following randomization
measure: Time to hospitalization
timeFrame: 28 days following randomization
measure: Length of hospitalization
timeFrame: 28 days following randomization
measure: Admission to intensive care
timeFrame: 28 days following randomization
measure: Adverse events
timeFrame: 28 days following randomization
measure: Serious adverse events
timeFrame: 28 days following randomization
Other outcomes:
Locations:
Study officials:
affiliation: Epicentre
name: Rebecca F Grais
role: STUDY_DIRECTOR
affiliation: Hôpital Général de Référence de Niamey
name: Eric Adehossi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05535283: Assessing Clinical Trial Experiences of Patients With Osteosarcoma
Official title: An Observational Study Investigating The Experiences of Patients In Osteosarcoma Clinical Trials
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Osteosarcoma
Keywords: osteosarcoma
Lead sponsor: Power Life Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2022-09-10
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Osteosarcoma patients who are actively considering enrolling in an interventional clinical trial, but have not yet completed enrollment and randomization.

Brief summary: Clinical study participation has historically been heavily biased toward specific demographics.

Several people will be invited to enroll in this study so that it may collect a variety of data about osteosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.

People with osteosarcoma who are invited to take part in medical research will benefit from the analysis of the data.


Eligibility criteria: Inclusion Criteria:

* Patient has been diagnosed with osteosarcoma
* Patient has self-identified as planning to enroll in an interventional clinical trial
* Patient is a minimum of 18 years or older

Exclusion Criteria:

* ECOG score of 4
* Patient is pregnant
* Inability to perform regular electronic reporting
* Patient does not understand, sign, and return consent form

Primary outcomes:
measure: Number of patients who decide to enroll in an osteosarcoma clinical trial
timeFrame: 3 months
measure: Rate of patients who remain in osteosarcoma clinical trial to trial completion
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Power Life Sciences Inc.
name: Michael B Gill
role: STUDY_DIRECTOR
References:
citation: Bielack S, Carrle D, Jost L; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii94-6. doi: 10.1093/annonc/mdn102. No abstract available.
citation: Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, Malawer MM. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002 Mar 15;65(6):1123-32.
citation: Burns L, Perisoglou M. Clinical trials in osteosarcoma treatment: patients' perspective through art. Recent Results Cancer Res. 2009;179:345-61. doi: 10.1007/978-3-540-77960-5_22.
Clinical trial NCT00583583: Emergency/Compassionate Use - AMPLATZER Duct Occluder
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Patent
Ductus
Arteriosus
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2007-12-31
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: Emergency/compassionate use for the AMPLATZER Duct Occluder


Eligibility criteria: Inclusion Criteria:

* Emergency/compassionate use for patients not meeting the inclusion crtieria for the AMPLATZER Duct Occluder clinical trial

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05106283: Comparison of Deep Serratus Anterior Plane Block and Combination of Deep and Superficial Serratus Anterior Plane Block
Official title: Comparison of the Effects of Ultrasound-Guided Deep Serratus Anterior Plane Block and Combination of Deep and Superficial Serratus Anterior Plane Block on Postoperative Acute Pain in Patients Undergoing Video-Assisted Thoracoscopic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Serratus Anterior Plane Block
Multimodal Analgesia
Thoracic Surgery, Video-Assisted
Keywords: Serratus Anterior Plane Block, Multimodal Analgesia, VATS
Lead sponsor: Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
Sponsor class: OTHER
First posted: 2021-11-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Video-assisted thoracic surgery (VATS) has become a common procedure in thoracic surgery. Severe postoperative pain may be encountered in patients undergoing VATS. Analgesic methods such as thoracic paravertebral block (TPVB), intercostal block, serratus anterior plane block (SAPB) and erector spina plane block (ESPB) are widely used for VATS. Among these methods, ultrasound (US) guided TPVB is the most preferred method. In recent years, the frequency of application of plane blocks as a component of multimodal analgesia has been increased. ESPB and SAPB are some of them. There are two techniques for SAPB application. In Deep SAPB (DSAPB) application, local anesthetic agent is given under the serratus anterior muscle. In the Superficial SAPB (SSAPB) application, the local anesthetic agent is given above the serratus anterior muscle. Since it is done by entering from the same point in two applications, it is possible to perform these two applications at the same time with a single needle entry. The mechanisms of regional analgesia techniques used after thoracic surgery operations are also different from each other. Therefore, it may be possible to obtain a more effective analgesic effect in patients by combining the mechanism of action of DSAPB and SSAPB , as in the multimodal analgesia method. This study seeks to evaluate the effect of DSAPB and combined DSAPB-SSAPB pain after VATS.


Eligibility criteria: Inclusion Criteria:

* 18 to 65 years old
* ASA physical status I-II-III
* BMI 18 to 30 kg/m2
* Elective video assisted thoracoscopic surgery

Exclusion Criteria:

* Patient refusing the procedure
* Emergency surgery
* Chronic opioid or analgesic use

Primary outcomes:
measure: Pain Scores
timeFrame: 48 hours after surgery
Secondary outcomes:
measure: Morphine Consumption
timeFrame: 24 hours after surgery
Other outcomes:
Locations:
city: Kecioren
country: Turkey
facility: Ankara Atatürk Chest Disease and Chest Surgery Training and Research Hospital
state: Ankara
Study officials:
affiliation: Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
name: Musa Zengin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02859883: Evaluation of Oesogastroduodenoscopy With Vision to 245 ° (Full Spectrum Endoscopy) to View the Main Disc and Accessory
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adenoma of the Accessory Papilla
Ampulloma of the Accessory Papilla
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2016-08-09
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient eligible to any upper gastrointestinal endoscopy diagnostic

Brief summary: The monitoring and prognosis of patients with familial polyposis adenomatous rests on analysis of the transitional mucosa at the anal margin and especially on the tracking, characterization and resection of lesions of dysplasia type of high grade at the duodenal level, after total proctocolectomy. Currently, endoscopes with axial or lateral vision are used. The FUSE technology allows the simplification or even the improvement of patient surveillance with a 245° vision (versus150° in case of classical gastroscope). The use of a second screen to enlarge the field of view may allow both analysis of duodenum and the main and accessory papilla with one single endoscope and to decrease the number of omitted lesions .


Eligibility criteria: Inclusion Criteria:

* Patient eligible to any upper gastrointestinal endoscopy diagnostic

Exclusion Criteria:

* History of duodenal or gastric surgery

Primary outcomes:
measure: Efficacy
timeFrame: 1 day
Secondary outcomes:
measure: Number of patient with treatment-related serious adverse events
timeFrame: 5 day
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli Calmettes
state: Bouches du Rhone
Study officials:
affiliation: Institut Paoli-Calmettes
name: Jean-Philippe RATONE, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gralnek IM, Segol O, Suissa A, Siersema PD, Carr-Locke DL, Halpern Z, Santo E, Domanov S. A prospective cohort study evaluating a novel colonoscopy platform featuring full-spectrum endoscopy. Endoscopy. 2013 Sep;45(9):697-702. doi: 10.1055/s-0033-1344395. Epub 2013 Aug 12.
citation: Gralnek IM, Siersema PD, Halpern Z, Segol O, Melhem A, Suissa A, Santo E, Sloyer A, Fenster J, Moons LM, Dik VK, D'Agostino RB Jr, Rex DK. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. Lancet Oncol. 2014 Mar;15(3):353-60. doi: 10.1016/S1470-2045(14)70020-8. Epub 2014 Feb 20.
citation: Moussata D, Napoleon B, Lepilliez V, Klich A, Ecochard R, Lapalus MG, Nancey S, Cenni JC, Ponchon T, Chayvialle JA, Saurin JC. Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis. Gastrointest Endosc. 2014 Nov;80(5):817-25. doi: 10.1016/j.gie.2014.03.012. Epub 2014 May 6.